Cyclopharm Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

James McBrayer

Chief executive officer

AU$893.5k

Total compensation

CEO salary percentage	52.7%
CEO tenure	16yrs
CEO ownership	4.9%
Management average tenure	6.1yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has James McBrayer's remuneration changed compared to Cyclopharm's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	AU$893k	AU$471k	-AU$5m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	n/a	n/a	-AU$7m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	AU$850k	AU$439k	-AU$7m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	n/a	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	AU$957k	AU$427k	-AU$5m
Sep 30 2021	n/a	n/a	-AU$5m
Jun 30 2021	n/a	n/a	-AU$4m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	AU$1m	AU$406k	-AU$6m
Sep 30 2020	n/a	n/a	-AU$6m
Jun 30 2020	n/a	n/a	-AU$6m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	AU$753k	AU$341k	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	n/a	n/a	-AU$2m
Mar 31 2019	n/a	n/a	-AU$1m
Dec 31 2018	AU$426k	AU$335k	-AU$35k
Sep 30 2018	n/a	n/a	-AU$409k
Jun 30 2018	n/a	n/a	-AU$782k
Mar 31 2018	n/a	n/a	-AU$1m
Dec 31 2017	AU$421k	AU$327k	-AU$2m

Compensation vs Market: James's total compensation ($USD591.74K) is above average for companies of similar size in the Australian market ($USD298.29K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James McBrayer (59 yo)

16yrs

Tenure

AU$893,462

Compensation

Mr. James S. McBrayer, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James McBrayer	CEO, MD	16yrs	AU$893.46k	4.9% A$ 9.3m
Mathew Farag	Chief Operating Officer	7.4yrs	AU$484.33k	0.46% A$ 880.0k
Graham Phillips	Finance Manager	no data	AU$152.73k	no data
Sally-Ann Cornelius	Head of Sales	4.8yrs	no data	no data
Niamh McAree	Head of Quality and Regulatory	4.8yrs	no data	no data
Chris Quinn	Head of Service	4.8yrs	no data	no data
Sui Cheah	Financial Controller	13.3yrs	AU$64.44k	no data
Lynn McLauchlin	General Manager of Canada	no data	AU$173.42k	no data
Gary Somerville	Quality & Regulatory Manager	no data	AU$151.96k	no data

6.1yrs

Average Tenure

Experienced Management: CYC's management team is seasoned and experienced (6.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James McBrayer	CEO, MD	16yrs	AU$893.46k	4.9% A$ 9.3m
Dianne Angus	Independent Non-Executive Director	2.8yrs	AU$60.76k	0.0092% A$ 17.6k
David Heaney	Independent Non-Executive Chairman	17.6yrs	AU$85.07k	0.26% A$ 492.8k
John Wigglesworth	Non-Executive Director	less than a year	no data	0.019% A$ 36.9k
Kevin M. Barrow	Independent Non-Executive Director	1.8yrs	AU$60.76k	0.010% A$ 19.4k
Gregory King	Independent Non-Executive Director	1.8yrs	AU$60.76k	0.0092% A$ 17.6k

2.3yrs

Average Tenure

64yo

Average Age

Experienced Board: CYC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Cyclopharm Management

Management criteria checks 1/4

Key information

Recent management updates

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Less than half of directors are independent

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

Recent updates

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: AU$0.051 loss per share (vs AU$0.072 loss in FY 2022)

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

New major risk - Share price stability

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.056 loss in FY 2021)

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Forecast to breakeven in 2024

Less than half of directors are independent

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

No longer forecast to breakeven

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

No longer forecast to breakeven

Forecast to breakeven in 2022

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age